- A multinational, phase 3 clinical trial – TALAPRO-2 – tested whether the combination of two medicines, talazoparib and enzalutamide, may improve clinical outcomes in adult men with metastatic castration-resistant prostate cancer.
- Treatment with talazoparib and enzalutamide resulted in a 37% reduced risk of cancer progression or death, compared to treatment with placebo and enzalutamide.
- The Food and Drug Administration (FDA)’s decision on whether or not this combination therapy may be…
Read the full article here
